Immuno-Oncology Service Charting Growth Trajectories: Analysis and Forecasts 2025-2033

Key Insights

The global immuno-oncology services market size was valued at USD 35.4 billion in 2025 and is projected to expand at a compound annual growth rate (CAGR) of 11.4% from 2025 to 2033. Increasing prevalence of cancer, technological advancements, growing government funding for research and development, and rising awareness of personalized medicine are the key factors driving the market growth. The increasing adoption of immunotherapy and targeted therapies is further expected to fuel the market demand.

Key market players include Crown Bioscience, Bio-Techne, Abcam, WuXi AppTec, Shanghai ChemPartner, George Clinical, Laboratory Corporation of America® Holdings, Medpace, Genscript, Shanghai Novamab Biopharmaceuticals, LIDE, and TransCure bioServices. These companies are focusing on developing innovative technologies and expanding their global presence to maintain their competitive edge. The market is fragmented, with a large number of small and medium-sized companies operating in the field.

Immuno-Oncology Service Trends

The global immuno-oncology service market is anticipated to expand rapidly, surging from $25 billion in 2023 to an astounding $150 billion by 2030, representing a CAGR of 25%. This unprecedented growth is attributed to several key factors, including:

• The rising prevalence of cancer worldwide
• Growing adoption of personalized cancer treatments
• Technological advancements in immuno-oncology research
• Increasing government funding for cancer research

Driving Forces: What's Propelling the Immuno-Oncology Service

Several driving forces are propelling the growth of the immuno-oncology service market:

• Rising Cancer Prevalence: Cancer remains one of the leading causes of death globally, accounting for over 10 million deaths annually. The increasing incidence of cancer is due to factors such as population growth, aging, and lifestyle changes.
• Demand for Personalized Treatment: Traditional cancer treatments have often been ineffective and associated with severe side effects. Immuno-oncology offers a more personalized and targeted approach, tailoring treatments to the specific characteristics of each patient's cancer.
• Technological Advancements: Advancements in gene sequencing, bioinformatics, and tumor analysis technologies have facilitated the development of more effective immuno-oncology treatments. These technologies enable researchers to better understand cancer antigens and develop therapies that harness the patient's own immune system to combat the disease.
• Government Funding: Governments worldwide are investing heavily in cancer research, including immuno-oncology. This funding supports research institutions, drug development, and clinical trials, driving innovation and accelerating the progress of immuno-oncology service providers.

Challenges and Restraints in Immuno-Oncology Service

Despite the promising potential of immuno-oncology, several challenges and restraints hinder market growth:

• High Cost of Treatments: Immuno-oncology therapies can be extremely expensive, limiting their accessibility for many patients.
• Limited Reimbursement: Reimbursement policies for immuno-oncology treatments vary widely, impacting their affordability and accessibility.
• Adverse Effects: Immuno-oncology treatments can cause severe adverse effects, such as cytokine release syndrome and immune-mediated adverse events. These effects require careful monitoring and management.

Key Region or Country & Segment to Dominate the Market

North America is expected to dominate the global immuno-oncology service market, with a share of over 40%. The high prevalence of cancer, access to advanced healthcare infrastructure, and strong government support for cancer research contribute to this region's dominance.

Basic research is projected to be the largest segment of the immuno-oncology service market, driven by the need for further understanding of the immune system and cancer biology.

• Key Players in the Immuno-Oncology Service:

  • Crown Bioscience ()
  • Bio-Techne ()
  • Abcam ()
  • WuXi AppTec ()
  • Shanghai ChemPartner ()
  • George Clinical ()
  • Laboratory Corporation of America®
  • Holdings ()
  • Medpace ()
  • Genscript ()
  • Shanghai Novamab
  • Biopharmaceuticals ()
  • LIDE ()
  • TransCure bioServices ()

• Significant Developments in Immuno-Oncology Service Sector:

  • FDA approval of new CAR T-cell therapies for various cancers
  • Advances in CRISPR-Cas9 gene editing for cancer treatment
  • Development of personalized cancer vaccines using mRNA technology

Immuno-Oncology Service Segmentation

• 1. Type
  • 1.1. Basic Research
  • 1.2. Clinical Research

Immuno-Oncology Service Segmentation By Geography

• 1. North America
  • 1.1. United States
  • 1.2. Canada
  • 1.3. Mexico
• 2. South America
  • 2.1. Brazil
  • 2.2. Argentina
  • 2.3. Rest of South America
• 3. Europe
  • 3.1. United Kingdom
  • 3.2. Germany
  • 3.3. France
  • 3.4. Italy
  • 3.5. Spain
  • 3.6. Russia
  • 3.7. Benelux
  • 3.8. Nordics
  • 3.9. Rest of Europe
• 4. Middle East & Africa
  • 4.1. Turkey
  • 4.2. Israel
  • 4.3. GCC
  • 4.4. North Africa
  • 4.5. South Africa
  • 4.6. Rest of Middle East & Africa
• 5. Asia Pacific
  • 5.1. China
  • 5.2. India
  • 5.3. Japan
  • 5.4. South Korea
  • 5.5. ASEAN
  • 5.6. Oceania
  • 5.7. Rest of Asia Pacific